TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05161507

Intervention type: PROCEDURE
Intervention: Magseed
Description: Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.

Intervention type: PROCEDURE
Intervention: Magtrace
Description: Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.

Intervention type: PROCEDURE
Intervention: Axillary lymph node metastasis - needle biopsy
Description: Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
Study: NCT04872829

Intervention type: DEVICE
Intervention: cataract surgery
Description: All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D.

Intervention type: DEVICE
Intervention: cataract surgery
Description: All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D.
Study: NCT03140735

Intervention type: OTHER
Group type: OTHER
Intervention: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
Description: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction

Intervention type: OTHER
Group type: OTHER
Intervention: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
Description: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction

Intervention type: OTHER
Group type: OTHER
Intervention: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
Description: Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
Study: NCT03514134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study: NCT03140735

Intervention type: OTHER
Group type: OTHER
Intervention: Control group without heart disease
Description: Control group without heart disease
Study: NCT03172052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA (2-mercaptoethane sulfonate Na)
Description: • Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA (2-mercaptoethane sulfonate Na)
Description: • Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
Study: NCT02686554

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: The patients perform tests to assess their cognitive abilities

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: The patients perform tests to assess their cognitive abilities
Study: NCT01123083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study: NCT04297982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala Activity
Description: Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
Study: NCT03730519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baroreflex Activation Therapy with Barostim Neo
Description: Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baroreflex Activation Therapy with Barostim Neo
Description: Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
Study: NCT04297982

Intervention type: OTHER
Group type: OTHER
Intervention: Routine nursing care
Description: Interventions routinely implemented by nurses in the clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing care
Description: Interventions routinely implemented by nurses in the clinic
Study: NCT04169763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Given PO
Study: NCT00913822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
Study: NCT03733548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX
Description: Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
Study: NCT00861887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Vancomycin
Description: Vancomycin treatment 125 mg po every 6 hours x 2 weeks
Study: NCT04178941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational outreach
Description: Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
Study: NCT02310295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: focal macular laser therapy
Study: NCT03172052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
Study: NCT00861887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vancomycin
Description: Vancomycin treatment 125 mg po every 6 hours x 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Vancomycin
Description: Vancomycin 125 mg every 6 hours x 2 weeks
Study: NCT03172052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video assisted thoracoscopy (VATS)
Description: Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
Study: NCT03172052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video assisted thoracoscopy (VATS)
Description: Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video assisted thoracoscopy (VATS)
Description: Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video assisted thoracoscopy (VATS)
Description: Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
Study: NCT02310295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: focal macular laser therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravitreal injection of Bevacizumab
Study: NCT02105311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
Study: NCT02498535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide 160 ppm
Description: Nitric Oxide 160 ppm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide 160 ppm
Description: Nitric Oxide 160 ppm
Study: NCT03052972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain
Study: NCT00655278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
Study: NCT02288208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral Therapy (tenofovir or entecavir)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiviral Therapy (tenofovir or entecavir)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for birinapant)
Study: NCT03829007

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PD-L1 imaging
Description: 89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
Study: NCT03288402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
Description: effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
Description: effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
Description: effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
Study: NCT02948725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education + standard rehabilitation
Study: NCT02978352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning
Study: NCT02310295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of Triamcinolone Acetonide
Study: NCT01138215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VZV vaccination
Description: Dose : 0.5 ml Route : subcutaneous injection (SC)
Study: NCT00755118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study: NCT03262961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 20 MG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT05967754

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: polysomnography
Description: polysomnography and serum uric acid measurement
Study: NCT03369158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient specific pedicle screw positioning guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free hand technique pedicle screw positioning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MUST pedicle screw

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUST pedicle screw
Study: NCT00980044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Oral Medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Oral Medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Medication
Study: NCT01296308

Intervention type: OTHER
Intervention: inpatient integrative treatment
Description: two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
Study: NCT03502681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Days 1, 15 Avelumab (10mg/kg)
Study: NCT01871649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: golimumab
Description: golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
Study: NCT00755118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study: NCT04090190

Intervention type: DRUG
Group type: OTHER
Intervention: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Description: Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
Study: NCT02614118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: 10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: 10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 45 minutes before root canal treatment
Study: NCT00457691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Description: 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 180mg/m2 iv day 1 every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo- leucovorin
Description: 200mg/m2 iv; day 1 every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 fluorouracil
Description: 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: irinotecan
Description: 180mg/m2 iv day 1 every 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levo- leucovorin
Description: 200mg/m2 iv; day 1 every 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
Study: NCT02644239

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketogenic diet
Description: Ketogenic diet with high fat (90%)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketogenic diet
Description: Ketogenic diet with high fat (90%)